CRISPR Therapeutics Reports $12.7 Million Revenue, Net Loss Per Share of $1. ...
Revenue of $12.7 million tops the $10.49 million analyst estimate, while the loss per share of $1.15 comes in wider than the projected $0.98 Related Stocks: CRSP ,
Revenue of $12.7 million tops the $10.49 million analyst estimate, while the loss per share of $1.15 comes in wider than the projected $0.98 Related Stocks: CRSP ,